PMID- 32722216
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2305-6320 (Print)
IS  - 2305-6320 (Electronic)
IS  - 2305-6320 (Linking)
VI  - 7
IP  - 8
DP  - 2020 Jul 24
TI  - Autologous Mesenchymal Stem Cell Treatment is Consistently Effective for the 
      Treatment of Knee Osteoarthritis: The Results of a Systematic Review of Treatment 
      and Comparison to a Placebo Group.
LID - 10.3390/medicines7080042 [doi]
LID - 42
AB  - Background: Numerous studies have used autologous mesenchymal stem cell 
      injections (AMSCI) to treat osteoarthritis. We hypothesized that AMSCI is an 
      effective osteoarthritis treatment with increasing efficacy at higher doses. 
      Methods: We conducted a PubMed search for human clinical studies using AMSCI for 
      the treatment of osteoarthritis (OA) and a second search for placebo arms of 
      injectate OA treatment. Inclusion criteria included treatment outcomes ratings 
      both pre-treatment and at least 6 months post-treatment. Results: 45 AMSCI 
      cohorts from 34 studies met criteria. All AMSCI cohorts showed improvement at 
      mean 15.3 months post-treatment. Mean WOMAC and VAS scores improved at 6-months 
      and at final follow-up (p < 0.0001 for all). Scores > 2 years were also 
      significant (WOMAC p = 0.001/VAS p = 0.004). Results greatly exceeded the minimal 
      clinically important difference (MCID) at each time point. AMSCI improvement also 
      substantially exceeded previously published 6-month placebo-treatment 
      improvement. No dose-response relationship was seen. AMSCI cohorts showed 
      continuing improvement >/= 6 months, and continued upward at one year. Placebo 
      scores were already trending downward by 6 months. Conclusions: AMSCI is a 
      consistently significantly effective treatment for osteoarthritis. It should no 
      longer be stated that data is insufficient to establish AMSCI efficacy for OA. 
      Given its excellent safety profile, AMSCI should be widely used for the treatment 
      of osteoarthritis.
FAU - Prodromos, Chadwick
AU  - Prodromos C
AD  - Illinois Sportsmedicine and Orthopaedic Center, Glenview, IL 60025, USA.
FAU - Finkle, Susan
AU  - Finkle S
AD  - Illinois Sportsmedicine and Orthopaedic Center, Glenview, IL 60025, USA.
FAU - Rumschlag, Tobias
AU  - Rumschlag T
AD  - Illinois Sportsmedicine and Orthopaedic Center, Glenview, IL 60025, USA.
FAU - Lotus, John
AU  - Lotus J
AD  - Illinois Sportsmedicine and Orthopaedic Center, Glenview, IL 60025, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200724
PL  - Switzerland
TA  - Medicines (Basel)
JT  - Medicines (Basel, Switzerland)
JID - 101671069
PMC - PMC7459966
OTO - NOTNLM
OT  - adipose tissue
OT  - autologous
OT  - bone marrow aspirate
OT  - knee osteoarthritis
OT  - mesenchymal stem cell
OT  - stem cell
COIS- The authors declare no conflict of interest.
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
PMCR- 2020/07/24
CRDT- 2020/07/30 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
PHST- 2020/07/24 00:00 [pmc-release]
AID - medicines7080042 [pii]
AID - medicines-07-00042 [pii]
AID - 10.3390/medicines7080042 [doi]
PST - epublish
SO  - Medicines (Basel). 2020 Jul 24;7(8):42. doi: 10.3390/medicines7080042.